Childhood neuroblastoma represents one of medicine's most challenging pediatric cancers, with amplified MYCN genes driving the most aggressive cases. The inability to directly target the problematic N-Myc protein has left clinicians with limited therapeutic options for these high-risk patients. This research reveals a previously unknown regulatory cascade that keeps cancer-driving N-Myc proteins stable within tumor cells. The investigation identified NeuroD1 as a master regulator that prevents N-Myc degradation through a sophisticated molecular mechanism. When NeuroD1 levels are high, it activates USP1, a deubiquitinating enzyme that removes cellular "destruction tags" from N-Myc proteins. Without these ubiquitin tags, N-Myc escapes normal cellular cleanup processes and accumulates to cancer-promoting levels. Laboratory experiments demonstrated that disrupting NeuroD1 function triggers rapid N-Myc breakdown through the proteasome degradation pathway. The research extends beyond mechanism discovery to therapeutic potential. Pimozide, an FDA-approved antipsychotic with known USP1-inhibiting properties, showed promising anti-tumor activity in neuroblastoma cell lines. This finding suggests existing medications might be repurposed for pediatric cancer treatment. The NeuroD1-USP1-MYCN axis represents a significant advance in neuroblastoma biology, offering the first viable indirect approach to neutralizing undruggable N-Myc. However, translation to clinical benefit requires demonstrating safety and efficacy in pediatric populations, where drug development faces unique regulatory and ethical constraints. The pathway's complexity also raises questions about potential resistance mechanisms and optimal combination strategies.